vs
Harmony Biosciences Holdings, Inc.（HRMY）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Harmony Biosciences Holdings, Inc.的季度营收约是Rapid7, Inc.的1.1倍（$243.8M vs $217.4M），Harmony Biosciences Holdings, Inc.净利率更高（9.2% vs 1.4%，领先7.8%），Harmony Biosciences Holdings, Inc.同比增速更快（21.1% vs 0.5%），Harmony Biosciences Holdings, Inc.自由现金流更多（$126.0M vs $36.4M），过去两年Harmony Biosciences Holdings, Inc.的营收复合增速更高（25.6% vs 3.0%）
哈莫尼生物科学控股公司是一家处于商业化阶段的生物制药企业，专注于罕见神经及中枢神经系统疾病创新疗法的研发与商业化，核心产品针对发作性睡病等睡眠相关中枢神经系统病症，主要市场为美国。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
HRMY vs RPD — 直观对比
营收规模更大
HRMY
是对方的1.1倍
$217.4M
营收增速更快
HRMY
高出20.6%
0.5%
净利率更高
HRMY
高出7.8%
1.4%
自由现金流更多
HRMY
多$89.6M
$36.4M
两年增速更快
HRMY
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $243.8M | $217.4M |
| 净利润 | $22.5M | $3.1M |
| 毛利率 | 71.9% | 68.9% |
| 营业利润率 | 15.8% | 1.0% |
| 净利率 | 9.2% | 1.4% |
| 营收同比 | 21.1% | 0.5% |
| 净利润同比 | -54.6% | 44.1% |
| 每股收益（稀释后） | $0.38 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRMYRPD
| Q4 25 | $243.8M | $217.4M | ||
| Q3 25 | $239.5M | $218.0M | ||
| Q2 25 | $200.5M | $214.2M | ||
| Q1 25 | $184.7M | $210.3M | ||
| Q4 24 | $201.3M | $216.3M | ||
| Q3 24 | $186.0M | $214.7M | ||
| Q2 24 | $172.8M | $208.0M | ||
| Q1 24 | $154.6M | $205.1M |
净利润HRMYRPD
| Q4 25 | $22.5M | $3.1M | ||
| Q3 25 | $50.9M | $9.8M | ||
| Q2 25 | $39.8M | $8.3M | ||
| Q1 25 | $45.6M | $2.1M | ||
| Q4 24 | $49.5M | $2.2M | ||
| Q3 24 | $46.1M | $15.4M | ||
| Q2 24 | $11.6M | $6.5M | ||
| Q1 24 | $38.3M | $1.4M |
毛利率HRMYRPD
| Q4 25 | 71.9% | 68.9% | ||
| Q3 25 | 75.1% | 70.2% | ||
| Q2 25 | 81.0% | 70.6% | ||
| Q1 25 | 82.7% | 71.7% | ||
| Q4 24 | 73.0% | 69.5% | ||
| Q3 24 | 77.0% | 70.6% | ||
| Q2 24 | 81.4% | 70.7% | ||
| Q1 24 | 82.2% | 70.3% |
营业利润率HRMYRPD
| Q4 25 | 15.8% | 1.0% | ||
| Q3 25 | 27.3% | 2.7% | ||
| Q2 25 | 24.0% | 1.6% | ||
| Q1 25 | 30.4% | -0.0% | ||
| Q4 24 | 27.7% | 3.4% | ||
| Q3 24 | 33.2% | 6.0% | ||
| Q2 24 | 12.4% | 2.5% | ||
| Q1 24 | 33.7% | 4.7% |
净利率HRMYRPD
| Q4 25 | 9.2% | 1.4% | ||
| Q3 25 | 21.2% | 4.5% | ||
| Q2 25 | 19.8% | 3.9% | ||
| Q1 25 | 24.7% | 1.0% | ||
| Q4 24 | 24.6% | 1.0% | ||
| Q3 24 | 24.8% | 7.2% | ||
| Q2 24 | 6.7% | 3.1% | ||
| Q1 24 | 24.8% | 0.7% |
每股收益（稀释后）HRMYRPD
| Q4 25 | $0.38 | $0.05 | ||
| Q3 25 | $0.87 | $0.15 | ||
| Q2 25 | $0.68 | $0.13 | ||
| Q1 25 | $0.78 | $0.03 | ||
| Q4 24 | $0.85 | $0.08 | ||
| Q3 24 | $0.79 | $0.21 | ||
| Q2 24 | $0.20 | $0.09 | ||
| Q1 24 | $0.67 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $775.3M | $474.7M |
| 总债务越低越好 | $163.7M | — |
| 股东权益账面价值 | $870.2M | $154.7M |
| 总资产 | $1.3B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资HRMYRPD
| Q4 25 | $775.3M | $474.7M | ||
| Q3 25 | $672.6M | $407.1M | ||
| Q2 25 | $565.3M | $511.7M | ||
| Q1 25 | $507.0M | $493.5M | ||
| Q4 24 | $467.2M | $521.7M | ||
| Q3 24 | $410.5M | $443.7M | ||
| Q2 24 | $346.9M | $442.6M | ||
| Q1 24 | $372.4M | $411.7M |
总债务HRMYRPD
| Q4 25 | $163.7M | — | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $172.1M | — | ||
| Q1 25 | $175.7M | — | ||
| Q4 24 | $179.3M | — | ||
| Q3 24 | $182.8M | — | ||
| Q2 24 | $186.4M | — | ||
| Q1 24 | $190.0M | — |
股东权益HRMYRPD
| Q4 25 | $870.2M | $154.7M | ||
| Q3 25 | $835.1M | $127.2M | ||
| Q2 25 | $773.1M | $90.4M | ||
| Q1 25 | $720.5M | $52.7M | ||
| Q4 24 | $659.2M | $17.7M | ||
| Q3 24 | $596.8M | $-5.1M | ||
| Q2 24 | $538.6M | $-52.6M | ||
| Q1 24 | $515.4M | $-86.4M |
总资产HRMYRPD
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.1B | $1.6B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $999.2M | $1.7B | ||
| Q3 24 | $928.1M | $1.6B | ||
| Q2 24 | $858.4M | $1.5B | ||
| Q1 24 | $847.0M | $1.5B |
负债/权益比HRMYRPD
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.2M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $126.0M | $36.4M |
| 自由现金流率自由现金流/营收 | 51.7% | 16.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.61× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $347.9M | $146.2M |
8季度趋势，按日历期对齐
经营现金流HRMYRPD
| Q4 25 | $126.2M | $37.6M | ||
| Q3 25 | $108.7M | $39.0M | ||
| Q2 25 | $79.3M | $47.5M | ||
| Q1 25 | $34.0M | $29.8M | ||
| Q4 24 | $75.6M | $63.8M | ||
| Q3 24 | $70.5M | $44.0M | ||
| Q2 24 | $42.6M | $32.9M | ||
| Q1 24 | $31.1M | $31.1M |
自由现金流HRMYRPD
| Q4 25 | $126.0M | $36.4M | ||
| Q3 25 | $108.7M | $34.8M | ||
| Q2 25 | $79.3M | $46.6M | ||
| Q1 25 | $33.9M | $28.4M | ||
| Q4 24 | $75.0M | $62.6M | ||
| Q3 24 | $70.5M | $42.6M | ||
| Q2 24 | $42.0M | $32.6M | ||
| Q1 24 | $31.1M | $30.4M |
自由现金流率HRMYRPD
| Q4 25 | 51.7% | 16.8% | ||
| Q3 25 | 45.4% | 16.0% | ||
| Q2 25 | 39.6% | 21.8% | ||
| Q1 25 | 18.3% | 13.5% | ||
| Q4 24 | 37.3% | 28.9% | ||
| Q3 24 | 37.9% | 19.9% | ||
| Q2 24 | 24.3% | 15.7% | ||
| Q1 24 | 20.1% | 14.8% |
资本支出强度HRMYRPD
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.1% | 0.6% | ||
| Q4 24 | 0.3% | 0.5% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.4% | 0.1% | ||
| Q1 24 | 0.0% | 0.3% |
现金转化率HRMYRPD
| Q4 25 | 5.61× | 12.01× | ||
| Q3 25 | 2.14× | 3.97× | ||
| Q2 25 | 1.99× | 5.70× | ||
| Q1 25 | 0.75× | 14.14× | ||
| Q4 24 | 1.53× | 29.36× | ||
| Q3 24 | 1.53× | 2.85× | ||
| Q2 24 | 3.68× | 5.03× | ||
| Q1 24 | 0.81× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRMY
暂无分部数据
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
